Outcomes of anti-vegf therapy in choroidal neovascularization after macular surgery

Duc Anh Hua, Antonio M. Casella, Maria H. Berrocal, Dennis Han, Rayan A. Alshareef, Hugo Quiroz-Mercado, J. Fernando Arevalo, Jay Chhablani

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Purpose: To report treatment outcomes of anti-vascular endothelial growth factor (VEGF) therapy in choroidal neovascularization (CNV) presenting after macular surgery. Methods: Retrospective analysis of 7 eyes of 7 patients, who were diagnosed to have CNV after macular surgery and were treated with anti-vascular endothelial growth factor therapy. Collected data included demographic details; history of present illness; surgical procedure; and clinical examination including visual acuity at presentation and follow-up with imaging and management. Main outcome measures were resolution of CNV activity at the last follow-up. Secondary outcomes included change in visual acuity at final follow-up from baseline, number of injections, treatment free interval, and adverse events. Results: Seven eyes of 7 patients (2 females and 5 males), which underwent macular surgery (4 macular hole repairs and 3 epiretinal membrane (ERM) removal), were included in this study. Two eyes had drusen at the time of surgery; however, five eyes had no preexisting conditions. Mean interval between surgery and CNV development was 21.07 ± 38.55 months (range, 2 months-9 years). All patients had undergone intravitreal antivascular endothelial growth factor injections (range, 2-15; mean number: 5.85) with one eye requiring additional photodynamic therapy (PDT) and focal laser. Visual acuity was unchanged with inactive CNV at the last visit in all eyes after anti-vascular endothelial growth factor therapy. The mean follow-up duration after the development of CNV was 35.5 months (range, 6.5 months-8 years). Conclusion: Choroidal neovascularization occurring after otherwise successful macular surgery is uncommon with unknown predisposing factors. This entity appears to have poor visual outcome with currently available anti-vascular endothelial growth factor therapy.

Original languageEnglish (US)
Pages (from-to)359-366
Number of pages8
JournalRetinal Cases and Brief Reports
Issue number4
StatePublished - 2018


  • Anti-VEGF
  • CNV
  • Choroidal neovascularization
  • Epiretinal membrane
  • Macula
  • Macular hole

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Outcomes of anti-vegf therapy in choroidal neovascularization after macular surgery'. Together they form a unique fingerprint.

Cite this